PMID- 17916196
OWN - NLM
STAT- MEDLINE
DCOM- 20080410
LR  - 20080807
IS  - 0007-0963 (Print)
IS  - 0007-0963 (Linking)
VI  - 157
IP  - 6
DP  - 2007 Dec
TI  - Treatment of pyoderma gangrenosum with intravenous immunoglobulin.
PG  - 1235-9
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is increasingly being used to treat 
      inflammatory and autoimmune disease. OBJECTIVES: To elucidate the efficacy of 
      IVIG as an adjunct treatment for pyoderma gangrenosum (PG). PATIENTS/METHODS: Ten 
      patients with PG were treated with IVIG at Johns Hopkins Department of 
      Dermatology. All patients had severe mutilating and/or refractory disease 
      requiring multi-agent therapy. The charts were reviewed retrospectively. RESULTS: 
      Seven of the ten patients had clearance of PG lesions in the setting of IVIG and 
      six of these patients maintained efficacy with repeated IVIG treatment. Five 
      patients complained of nausea with treatment, and in one case nausea was severe 
      and intractable. One patient developed an immune reaction requiring 
      diphenhydramine and methylprednisolone and another experienced aseptic 
      meningitis. CONCLUSIONS: IVIG may be an effective adjuvant in the treatment of PG 
      and has an acceptable side-effect profile. Randomized, placebo-controlled, 
      double-blinded trials are needed to confirm this hypothesis.
FAU - Cummins, D L
AU  - Cummins DL
AD  - Department of Dermatology, Johns Hopkins Medical Institutions, 601 North Caroline 
      Street, Suite 6042, Baltimore, MD 21287, USA.
FAU - Anhalt, G J
AU  - Anhalt GJ
FAU - Monahan, T
AU  - Monahan T
FAU - Meyerle, J H
AU  - Meyerle JH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20071004
PL  - England
TA  - Br J Dermatol
JT  - The British journal of dermatology
JID - 0004041
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
CIN - Br J Dermatol. 2008 Apr;158(4):856-7. PMID: 18241257
MH  - Adolescent
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Perineum
MH  - Pyoderma Gangrenosum/pathology/*therapy
MH  - Treatment Outcome
RF  - 21
EDAT- 2007/10/06 09:00
MHDA- 2008/04/11 09:00
CRDT- 2007/10/06 09:00
PHST- 2007/10/06 09:00 [pubmed]
PHST- 2008/04/11 09:00 [medline]
PHST- 2007/10/06 09:00 [entrez]
AID - BJD8217 [pii]
AID - 10.1111/j.1365-2133.2007.08217.x [doi]
PST - ppublish
SO  - Br J Dermatol. 2007 Dec;157(6):1235-9. doi: 10.1111/j.1365-2133.2007.08217.x. 
      Epub 2007 Oct 4.